VRPX
Income statement / Annual
Last year (2024), Virpax Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Virpax Pharmaceuticals, Inc.'s net income was -$12.07 B.
See Virpax Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.82 B
|
$5.12 M
|
$10.76 M
|
$4.84 M
|
$1.29 M
|
$622,741.00
|
$1.14 M
|
| General & Administrative Expenses |
$6.26 B
|
$7.82 M
|
$11.08 M
|
$7.19 M
|
$2.90 M
|
$2.56 M
|
$1.48 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.26 B
|
$7.82 M
|
$11.08 M
|
$7.19 M
|
$2.90 M
|
$2.56 M
|
$1.48 M
|
| Other Expenses |
$0.00
|
$2.75 M
|
$194,413.00
|
$62,259.00
|
$4,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$12.08 B
|
$15.69 M
|
$21.85 M
|
$12.03 M
|
$4.20 M
|
$3.18 M
|
$2.63 M
|
| Cost And Expenses |
$0.00
|
$15.69 M
|
$21.85 M
|
$12.03 M
|
$4.20 M
|
$3.18 M
|
$2.63 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$92.82
|
$147.93
|
$124.64
|
$0.00
|
| Interest Expense |
-$103.75 M
|
$0.00
|
$0.00
|
$92,822.00
|
$147,934.00
|
$124,644.00
|
$14,976.00
|
| Depreciation & Amortization |
$0.00
|
$500,279.00
|
$18.35 M
|
$12.03 M
|
$4.20 M
|
$3.18 M
|
$2.63 M
|
| EBITDA |
-$12.08 B |
-$15.19 M |
$0.00 |
$0.00 |
-$4.19 M |
$0.00 |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$12.71 M
|
$500,280.00
|
$194,413.00
|
-$30,563.00
|
-$143,934.00
|
-$124,644.00
|
-$14,976.00
|
| Income Before Tax |
-$12.07 B
|
-$15.19 M
|
-$21.65 M
|
-$12.06 M
|
-$4.34 M
|
-$3.31 M
|
-$2.64 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$194,413.00
|
$92,822.00
|
$147,934.00
|
$124,644.00
|
-$161,141.00
|
| Net Income |
-$12.07 B
|
-$15.19 M
|
-$21.46 M
|
-$12.15 M
|
-$4.49 M
|
-$3.43 M
|
-$2.64 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2836.41 |
-12.97 |
-18.32 |
-10.37 |
-9.07 |
-6.58 |
-0.53 |
| EPS Diluted |
-2836.41 |
-12.97 |
-18.32 |
-10.37 |
-9.07 |
-6.58 |
-0.53 |
| Weighted Average Shares Out |
$4.25 M
|
$1.17 M
|
$1.17 M
|
$1.17 M
|
$494,515.00
|
$521,515.00
|
$4.95 M
|
| Weighted Average Shares Out Diluted |
$4.25 M
|
$1.17 M
|
$1.17 M
|
$1.17 M
|
$494,515.00
|
$521,515.00
|
$4.95 M
|
| Link |
|
|
|
|
|
|
|
